NCT03829436 - TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

September 7, 2022

Study Completion Date

September 7, 2022

Conditions

Hepatocellular CarcinomaMetastatic Castration Resistant Prostate CancerRenal Cell CarcinomaNon-small Cell Lung CancerColorectal CancerSquamous Cell Carcinoma of Head and NeckTriple-Negative Breast CancerUrothelial CarcinomaCholangiocarcinomaGastroEsophageal CancerPancreatic CancerSarcoma

Interventions

DRUG

Part 1 TPST-1120

Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression

DRUG

Part 2 TPST-1120 + nivolumab

Subjects will receive escalating doses of TPST-1120 administered orally twice daily

DRUG

Part 3 TPST-1120

Selected dose of TPST-1120 administered orally twice daily until disease progression

DRUG

Part 4 TPST-1120 + nivolumab

Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression

Trial Locations (11)

10024

Columbia University Medical Center, New York

15213

UPMC Hillman Cancer Center, Pittsburgh

19104

University of Pennsylvania Perelman School of Medicine, Philadelphia

19107

Thomas Jefferson University Hospital, Philadelphia

21287

Johns Hopkins University, Baltimore

28078

Carolina BioOncology Institute, Huntersville

33176

Miami Cancer Institute, Miami

37203

Sarah Cannon Research Institute - TN, Nashville

48109

University of Michigan Rogel Cancer Center, Ann Arbor

73104

Stephenson Cancer Center, Oklahoma City

94158

University of California - San Francisco, San Francisco